Moderna, Merck present positive phase IIb data on neoantigen cancer vaccine + Keytruda for melanoma

Phase III trial of subcutaneous pembrolizumab with berahyaluronidase alfa meets primary endpoints

Merck announced positive topline results from the pivotal phase III MK-3475A-D77 trial.

November 22, 2024

Remote telemedicine tool found highly accurate in diagnosing melanoma

Collecting images of suspicious-looking skin growths and sending them off-site for specialists to analyze is as accurate in identifying skin cancers as having a dermatologist examine them in person, a new study shows.

November 22, 2024

Vol.50 No.44

Clinical Roundup

UVA Health tests focused ultrasound to increase immune response in melanoma

A research team at UVA Health is testing the ability of focused ultrasound to increase the immune response to immunotherapy in melanoma. UVA’s work with focused ultrasound already has led to life-changing new treatments for Parkinson’s disease and essential tremor and pushed the technology to the forefront of medical research.

November 22, 2024

Vol.50 No.44

Clinical Roundup

Keytruda improves outcomes in soft tissue sarcoma

Addition of the immunotherapy drug pembrolizumab (Keytruda) to standard of care for patients with advanced soft tissue sarcoma of the limb significantly improved disease-free survival, according to the results of the SU2C-SARC032 clinical trial led by researchers from the University of Pittsburgh, UPMC, Duke University, and Princess Margaret Cancer Centre.

November 15, 2024

Vol.50 No.43

Clinical Roundup

Phase I clinical trial of Keytruda + Lymphir for recurrent solid tumors yields positive preliminary results

Promising preliminary results from an ongoing investigator-initiated phase I clinical trial evaluating the safety and efficacy of a combined regimen of Keytrua (pembrolizumab) and Lymphir (denileukin diftitox-cxdl or E7777) in patients with recurrent solid tumors were announced.

November 15, 2024

Vol.50 No.43

Drugs & Targets

EC approves Keytruda combinations for endometrial carcinoma indication, FIGO 2014 stage III-IVA locally advanced cervical cancer

The European Commission has approved two new indications for Keytruda (pembrolizumab), an anti-PD-1 therapy, in gynecologic cancers.

October 25, 2024

Vol.50 No.40

Moderna, Merck present positive phase IIb data on neoantigen cancer vaccine + Keytruda for melanoma

YOU MAY BE INTERESTED IN

Phase III trial of subcutaneous pembrolizumab with berahyaluronidase alfa meets primary endpoints

Remote telemedicine tool found highly accurate in diagnosing melanoma

UVA Health tests focused ultrasound to increase immune response in melanoma

Keytruda improves outcomes in soft tissue sarcoma

Phase I clinical trial of Keytruda + Lymphir for recurrent solid tumors yields positive preliminary results

EC approves Keytruda combinations for endometrial carcinoma indication, FIGO 2014 stage III-IVA locally advanced cervical cancer

Renew today!

Subscriber content

Never miss an issue!

Login